Compound Radar

RadNet, Inc. (RDNT) Stock Analysis

Price $71.97
Market cap $5.66B
Next earnings Nov 5, 2026
Entry status Wait $64.08–$67.02

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

42
42/100 Avoid
  • Financial Health 20
  • Profitability 50
  • Business Quality 60
  • Balance Sheet 30
  • Cash Flow 80

Why this rating?

Health 42/100 — Avoid

Strongest Cash Flow 80/100
Softest Financial Health 20/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

RadNet, Inc. (RDNT) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates RadNet, Inc. 42/100 (Avoid) due to solid business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Strong
  • Balance Sheet Stretched
  • Valuation Elevated

Financial highlights

Valuation

  • Forward P/E 81.17
  • PEG 0.96
  • EV/Revenue 3.33

Profitability

  • Revenue Growth 25.0%
  • Gross Margin 17.3%
  • Operating Margin 7.9%
  • Net Margin -0.9%
  • ROE 1.5%

Financial strength

  • Cash $726.27M
  • Debt $2.18B
  • Net Cash $-1.46B
  • Free Cash Flow $85.57M
  • Current Ratio 1.48

Similar companies

Peers in Diagnostics & Research, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Diagnostics & Research →

FAQ

How Compound Radar scores and tracks RadNet, Inc. (RDNT).

View Methodology & FAQ →